Allan Camaisa serves as Chairman of the Board of Directors and has been the CEO of Calidi Biotherapeutics since November 2017. Allan was an early investor in Calidi, and determined to bring a cure for difficult-to-treat cancers to market after losing his own father to cancer. As Chairman and CEO, he has successfully led a $20M early-stage Series A round and has been actively involved in recruiting key Board Members and leading MD’s and PhD’s to the Company’s Scientific Advisory Board. Allan’s background includes leading the Calidi Bio team in successful license negotiations with large pharmaceutical firms, and signing a collaboration agreement with the National Institutes of Health. Previously, Mr. Camaisa held the titles of CEO and Chairman at Parallel6, Inc., a digital mobile/cloud software platform for managing pharmaceutical patient clinical trials, which sold to PRA Health Sciences in 2017. In 2005, Allan founded and served as CEO at a software security company for managing digital access to medical records: Anakam, Inc., which sold a global license to the Veterans Affairs administration, and other clients including the Center for Medicare and Medicaid (CMS), before being acquired by Equifax in 2010 and receiving an Inc. 500 award. Prior, Mr. Camaisa founded and served as CEO at High Technology Solutions, a software systems integrator, which he grew from two to 500 employees and $50 million in revenue between 1992 and 2003. HTS received the Inc. 500 award for three consecutive years in a row. His accomplishments as a serial startup-bootstrapper, tech entrepreneur, and investor, further include four successful exits sold to publicly-traded Fortune 1000 companies, authorship of seven US patents, and an Ernst & Young Entrepreneur of the Year award. Before beginning his career in business, Mr. Camaisa served eight years as a surface warfare officer in the US Navy. He is a graduate of both the US Naval Academy and the Owner/President Management program at Harvard Business School.
Chairman of the Board — Appointed April 2018 (and Board Member since August 2015)